QurAlis
Cambridge, US · 2 known investors
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.
BiotechDeep TechMedical Devices
Founders & leadership
KE
Kevin EgganCo-founder
R
RoetCo-founder
W
WoolfCo-founder
Investors · 2
In the news
- Sell or Invest in QurAlis Stock Pre-IPOnasdaqprivatemarket.com · 2026
- QurAlis - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2024
- QurAlis to tap $88M funding to develop ALS product candidatesdrugdiscoverytrends.com · 2023
- Drug developer QurAlis raises $88 mln in Sanofi-backed funding round | Reutersreuters.com · 2023
- QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS) - QurAlisquralis.com · 2020
- QurAlis Raises $5.5M in Seed Funding - FinSMEsfinsmes.com · 2018